3 articles
The Delhi High Court refused Novo Nordisk interim relief against Dr Reddy’s, finding that the Semaglutide species patent faces serious validity challenges in light of the earlier genus…
The Delhi High Court’s decision in Novo Nordisk AS vs. Union of India addresses key procedural and substantive aspects of post grant patent opposition in India. The judgment…
The US Supreme Court’s decision in Caraco vs. Novo Nordisk clarifies the rights of generic drug manufacturers to challenge overly broad patent claims. This case marks a significant…